12/4
02:42 pm
beam
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]
Low
Report
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]
11/27
07:07 pm
beam
Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]
Low
Report
Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]
11/26
06:43 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
11/24
09:07 am
beam
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.
11/18
08:09 am
beam
Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]
Low
Report
Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]
11/17
11:03 am
beam
Beam Therapeutics (NASDAQ:BEAM) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..
11/12
07:00 am
beam
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Low
Report
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
11/10
08:28 pm
beam
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results [Yahoo! Finance]
Medium
Report
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results [Yahoo! Finance]
11/4
07:00 am
beam
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Medium
Report
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
11/3
09:00 am
beam
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Medium
Report
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
10/17
08:10 pm
beam
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet [Yahoo! Finance]
High
Report
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet [Yahoo! Finance]
10/13
03:34 pm
beam
Beam Therapeutics (NASDAQ:BEAM) had its price target lowered by analysts at JPMorgan Chase & Co. from $48.00 to $46.00. They now have an "overweight" rating on the stock.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its price target lowered by analysts at JPMorgan Chase & Co. from $48.00 to $46.00. They now have an "overweight" rating on the stock.
10/11
08:20 pm
beam
Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves [Yahoo! Finance]
Low
Report
Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves [Yahoo! Finance]
10/11
10:26 am
beam
Jim Cramer on Beam Therapeutics: “That's the Speculative Bottom There” [Yahoo! Finance]
Low
Report
Jim Cramer on Beam Therapeutics: “That's the Speculative Bottom There” [Yahoo! Finance]
10/10
08:06 am
beam
Beam Therapeutics (NASDAQ:BEAM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/9
12:14 pm
beam
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.00 price target on the stock.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $41.00 price target on the stock.
10/8
12:15 pm
beam
Beam Therapeutics (NASDAQ:BEAM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
01:09 am
beam
What Does Wall Street Think About Beam Therapeutics (BEAM)? [Yahoo! Finance]
Medium
Report
What Does Wall Street Think About Beam Therapeutics (BEAM)? [Yahoo! Finance]
9/23
09:17 am
beam
Treating High Cholesterol Could Become A One-And-Done Treatment [Forbes]
Low
Report
Treating High Cholesterol Could Become A One-And-Done Treatment [Forbes]
9/15
08:06 am
beam
Beam Therapeutics (NASDAQ:BEAM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/14
08:46 am
beam
Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program [Yahoo! Finance]
Medium
Report
Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program [Yahoo! Finance]
9/14
01:08 am
beam
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at
Wall Stree
9/9
04:52 am
beam
Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript [Seeking Alpha]
Low
Report
Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript [Seeking Alpha]
9/6
03:31 am
beam
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at
Wall Street
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at
Wall Street